These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 2179855)

  • 1. Clinical experience with Haemophilus influenzae type b conjugate vaccines.
    Mäkelä PH; Eskola J; Peltola H; Takala AK; Käyhty H
    Pediatrics; 1990 Apr; 85(4 Pt 2):651-3. PubMed ID: 2179855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease caused by Haemophilus influenzae type b in the immediate period after homologous immunization: immunologic investigation.
    Sood SK; Daum RS
    Pediatrics; 1990 Apr; 85(4 Pt 2):698-704. PubMed ID: 2107522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease.
    Eskola J; Käyhty H; Takala AK; Peltola H; Rönnberg PR; Kela E; Pekkanen E; McVerry PH; Mäkelä PH
    N Engl J Med; 1990 Nov; 323(20):1381-7. PubMed ID: 2233904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate): immunogenicity and safety at various doses.
    Yogev R; Arditi M; Chadwick EG; Amer MD; Sroka PA
    Pediatrics; 1990 Apr; 85(4 Pt 2):690-3. PubMed ID: 2107520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interchangeability of Haemophilus influenzae type b vaccines in the primary series: evaluation of a two-dose mixed regimen.
    Bewley KM; Schwab JG; Ballanco GA; Daum RS
    Pediatrics; 1996 Nov; 98(5):898-904. PubMed ID: 8909483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of a new Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) (PedvaxHIB).
    Vella PP; Staub JM; Armstrong J; Dolan KT; Rusk CM; Szymanski S; Greer WE; Marburg S; Kniskern PJ; Schofield TL
    Pediatrics; 1990 Apr; 85(4 Pt 2):668-75. PubMed ID: 2107517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective efficacy of Haemophilus influenzae type b polysaccharide vaccine.
    Shapiro ED; Berg AT
    Pediatrics; 1990 Apr; 85(4 Pt 2):643-7. PubMed ID: 2179854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of Haemophilus influenzae type b capsular polysaccharide vaccines in 18-month-old infants.
    Hendley JO; Wenzel JG; Ashe KM; Samuelson JS
    Pediatrics; 1987 Sep; 80(3):351-4. PubMed ID: 3306597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy.
    Eskola J; Peltola H; Takala AK; Käyhty H; Hakulinen M; Karanko V; Kela E; Rekola P; Rönnberg PR; Samuelson JS
    N Engl J Med; 1987 Sep; 317(12):717-22. PubMed ID: 3306379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland.
    Peltola H; Käyhty H; Sivonen A; Mäkelä H
    Pediatrics; 1977 Nov; 60(5):730-7. PubMed ID: 335348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opsonophagocidal activity in sera from infants and children immunized with Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate).
    Gray BM
    Pediatrics; 1990 Apr; 85(4 Pt 2):694-7. PubMed ID: 2107521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) (PedvaxHIB): clinical evaluation.
    Ahonkhai VI; Lukacs LJ; Jonas LC; Matthews H; Vella PP; Ellis RW; Staub JM; Dolan KT; Rusk CM; Calandra GB
    Pediatrics; 1990 Apr; 85(4 Pt 2):676-81. PubMed ID: 2107518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of antibody and booster responses to reimmunization with Haemophilus influenzae type b polysaccharide and polysaccharide diphtheria toxoid conjugate vaccines in children initially immunized at 15 to 24 months of age.
    Berkowitz CD; Ward JI; Chiu CE; Marcy SM; Gordon L; Hendley JO; Meier K; Marchant CD; McVerry P
    Pediatrics; 1990 Mar; 85(3):288-93. PubMed ID: 2304781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a Haemophilus influenzae type B polysaccharide-tetanus toxoid conjugate vaccine combined with diphtheria, tetanus and pertussis vaccines in Thai infants.
    Chotpitayasunondh T; Panpitpat C; Thisyakorn U; Furer E; Que JU; Hasler T; Cryz SJ
    Southeast Asian J Trop Med Public Health; 1997 Mar; 28(1):91-8. PubMed ID: 9322290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Passive immunization for infection with Haemophilus influenzae type b.
    Santosham M; Reid R; Letson GW; Wolff MC; Siber G
    Pediatrics; 1990 Apr; 85(4 Pt 2):662-6. PubMed ID: 2179857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of two Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccines (PRP-T) given with diphtheria-tetanus-pertussis vaccine to young Papua New Guinean children.
    Lehmann D; Kakazo M; Saleu G; Taime J; Javati A; Namuigi P; Alpers MP; Wegmüller B; Zellmeyer M; Fürer E; Que JU; Herzog C
    P N G Med J; 2001; 44(1-2):6-16. PubMed ID: 12418673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of Haemophilus b conjugate vaccine (meningococcal protein conjugate) in children with prior invasive Haemophilus influenzae type b disease.
    Walter EB; Moggio MV; Drucker RP; Wilfert CM
    Pediatr Infect Dis J; 1990 Sep; 9(9):632-5. PubMed ID: 2235187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody responses to Haemophilus influenzae type B vaccines in men with human immunodeficiency virus infection.
    Steinhoff MC; Auerbach BS; Nelson KE; Vlahov D; Becker RL; Graham NM; Schwartz DH; Lucas AH; Chaisson RE
    N Engl J Med; 1991 Dec; 325(26):1837-42. PubMed ID: 1683682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and reactogenicity of four Haemophilus influenzae type b capsular polysaccharide vaccines in Finnish 24-month-old children.
    Käyhty H; Peltola H; Eskola J
    Pediatr Infect Dis J; 1988 Aug; 7(8):574-7. PubMed ID: 3050853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization with Haemophilus influenzae type b polysaccharide vaccine at 18 and 24 months of age: evidence of decreased immunogenicity.
    Adderson EE; Chisholm N; Halperin SA
    Clin Invest Med; 1991 Aug; 14(4):338-45. PubMed ID: 1782732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.